The glycolytic gene expression profile is characteristic of aggressive triple-negative breast tumors that are associated with greater mortality than ER-positive tumors [49], but we found that high expression of these eight genes was also associated with significantly shorter recurrence- and distant metastasis-free survival in patients with ER-positive breast tumors, indicating a potentially relevant, aggressive subset of ER-positive breast cancer associated with some FGF1 target genes in endocrine-resistant breast cancer cells (Fig. 9D). Here, FGF1 is linked to breast carcinoma.